| NCT ID | NCT03023371 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College Hospital |
| Condition | IgG4-Related Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 900 participants |
| Start Date | 2016-12 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 900 participants in total. It began in 2016-12 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to establish a nation-wide cohort study of IgG4-related disease (IgG4-RD) in China. Methods: All the patients fulfilling diagnostic criteria of IgG4-RD (2011) would be enrolled from multi-centers around China. A online database system has been established. Endpoints: The primary endpoint is to investigate the clinical manifestations of Chinese IgG4-RD patients; the secondary endpoints including the demographic features,laboratory characteristics, immunological tests, imaging and pathological features, in addition, the treatment and prognosis of the disease.
Eligibility Criteria
Inclusion Criteria: * Conforming to the diagnostic criteria of IgG4-RD (2011); Exclusion Criteria: * Excluding other mimicing IgG4-RD, including tumors, vasculitis and sarcoidosis.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03023371 clinical trial?
This trial is open to participants of all sexes, studying IgG4-Related Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03023371 currently recruiting?
Yes, NCT03023371 is actively recruiting participants. Contact the research team at feiyunyun2013@hotmail.com for enrollment information.
Where is the NCT03023371 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT03023371 clinical trial?
NCT03023371 is sponsored by Peking Union Medical College Hospital. The trial plans to enroll 900 participants.